Analysts expect Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to announce ($0.90) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alder Biopharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.38) and the highest estimate coming in at ($0.60). Alder Biopharmaceuticals posted earnings of ($0.91) per share during the same quarter last year, which would suggest a positive year over year growth rate of 1.1%. The business is expected to issue its next earnings report on Monday, November 4th.

On average, analysts expect that Alder Biopharmaceuticals will report full year earnings of ($4.13) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($3.32). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.98) per share, with EPS estimates ranging from ($4.63) to ($1.45). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Alder Biopharmaceuticals.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.99) by $0.27.

Several equities research analysts have recently commented on ALDR shares. Cowen set a $18.00 price objective on Alder Biopharmaceuticals and gave the company a “buy” rating in a report on Friday, May 3rd. Zacks Investment Research upgraded Alder Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective for the company in a report on Friday, August 9th. Credit Suisse Group restated a “neutral” rating on shares of Alder Biopharmaceuticals in a report on Wednesday, July 10th. Leerink Swann started coverage on Alder Biopharmaceuticals in a report on Tuesday, May 28th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Mizuho restated a “hold” rating and set a $15.00 price objective on shares of Alder Biopharmaceuticals in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.88.

Shares of NASDAQ ALDR traded up $0.34 during midday trading on Friday, hitting $9.59. 472,000 shares of the stock traded hands, compared to its average volume of 725,061. The company has a market cap of $773.64 million, a PE ratio of -1.97 and a beta of 2.50. Alder Biopharmaceuticals has a one year low of $8.65 and a one year high of $18.95. The business has a 50 day moving average price of $10.46 and a two-hundred day moving average price of $12.14. The company has a debt-to-equity ratio of 1.74, a quick ratio of 8.94 and a current ratio of 8.94.

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its stake in Alder Biopharmaceuticals by 22.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $11,910,000 after purchasing an additional 215,098 shares in the last quarter. Stifel Financial Corp bought a new position in Alder Biopharmaceuticals during the 4th quarter worth $154,000. Legal & General Group Plc increased its position in Alder Biopharmaceuticals by 7.3% during the 4th quarter. Legal & General Group Plc now owns 24,842 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 1,698 shares during the period. Norges Bank bought a new position in Alder Biopharmaceuticals during the 4th quarter worth $1,203,000. Finally, Rhumbline Advisers increased its position in Alder Biopharmaceuticals by 10.3% during the 1st quarter. Rhumbline Advisers now owns 107,797 shares of the biopharmaceutical company’s stock worth $1,471,000 after buying an additional 10,035 shares during the period.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Recommended Story: Operating Income

Get a free copy of the Zacks research report on Alder Biopharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.